SCHEMBL5263593

SCHEMBL5263593

Cc1cc(Nc2ccnc(Nc3cccc(-c4nc5ccccc5s4)c3)n2)n[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 9/20 1.00
KDR P35968 6/20 1.00
FLT4 P35916 6/20 1.00
AURKB Q96GD4 5/20 1.00
IGF1R P08069 5/20 1.00
SRC P12931 5/20 1.00
INSR P06213 4/20 1.00
EGFR P00533 4/20 1.00
EPHB4 P54760 3/20 0.61
TEK Q02763 2/20 0.61
PDGFRB P09619 1/20 0.61
ITK Q08881 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
GAA P10253 1/20 0.47
RAB9A P51151 1/20 0.47
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260098 0.90 AURKA (1.00) AURKAKDRFLT4AURKBIGF1R
SCHEMBL5258236 0.84 AURKA (0.78) AURKAKDRFLT4AURKBIGF1R
SCHEMBL14602748 0.83 AURKA (1.00) AURKAKDRFLT4AURKBIGF1R
SCHEMBL5257695 0.82 KDR (0.78) AURKAKDRFLT4AURKBIGF1R
SCHEMBL5262114 0.80 AURKA (1.00) AURKAKDRFLT4AURKBIGF1R
SCHEMBL14621212 0.79 AURKA (0.65) AURKAKDRFLT4AURKBIGF1R
SCHEMBL5262588 0.76 AURKA (1.00) AURKAKDRFLT4AURKBIGF1R
SCHEMBL5259397 0.75 SMN1; SMN2 (0.60) AURKAKDRFLT4AURKBIGF1R
SCHEMBL5260039 0.72 AURKA (0.80) AURKAKDRFLT4AURKBIGF1R
SCHEMBL4603791 0.72 AURKA (0.65) AURKAKDRFLT4AURKBIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 AURKA 493/4885KDR 429/4885FLT4 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.